TrialMovement disorders : official journal of the Movement Disorder Society2022

A Randomized First-in-Human Study With UB-312, a UBITh® α-Synuclein Peptide Vaccine.

Hui Jing Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.